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ABSTRACT
With newer research-based classification systems, the term Vascular Cognitive Impairment (VCI) is now preferred to vascular de-
mentia. VCI is an umbrella term that includes all forms of cognitive deficits ranging from mild cognitive impairment of vascular 
origin (VaMCI) to vascular dementia (VaD). 
The new VCI construct takes into account the fact that in addition to single strategic infarcts, multiple infarcts, and leukoaraiosis, 
there are other mechanisms of cerebrovascular disease such as chronic hypoperfusion that might account for the pattern of 
cognitive deficits associated with vascular dementia. The key to defining the spectrum of VCI is neuropsychological testing, 
bedside or office-based clinical examination, and neuroimaging. The lack of specific cognitive tools that are sufficiently sensitive 
to detect subtle deficits makes the assessment of cognitive impairment difficult. Prospective cross-sectional and longitudinal 
studies of VCI from different settings are therefore required.
Although there have been few published reports, behavioural and psychological symptoms (BPS) are inherently present in VCI 
from the onset and during the course of the disease. Besides the type of population (i.e. clinical, community or nursing-home 
settings), the definition of VCI/VaD and the instruments used, and differences in the prevalence and pattern of BPS between 
various studies, could be due to other, often unconsidered, factors such as gender, age, education, use of medication and VCI/ 
/VaD severity. 
Key words: vascular dementia, mild cognitive impairment, stroke, cerebrovascular disorders, cognition, behaviour, dementia, 
multi-infarct, mixed dementia
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Introduction
The construct ‘vascular cognitive impairment’ (VCI) was 
introduced to comprise a heterogeneous group of cognitive 
disorders that share a presumed vascular cause; this includes 
both dementia and cognitive impairment without dementia. 
The most severe form of VCI is vascular dementia (VaD), and 
new subtypes with milder cognitive symptoms such as vascular 
mild cognitive impairment (i.e. VaMCI) are gradually being 
defined. The new VCI construct takes into account the fact that 
in addition to single strategic infarcts, multiple infarcts, and 
leukoaraiosis, also chronic hypoperfusion might account for 
the pattern of cognitive deficits associated with VaD. Hence, 
VCI is an umbrella term that includes all forms of cognitive 
deficits ranging from VaMCI to VaD [1, 2]. Different magnetic 
resonance imaging techniques remain crucial for the determi-
nation of vascular pathology using both well-established [3] 
and more innovative approaches [4]. 
VCI is used for all forms of cognitive disorder associ-
ated with cerebrovascular disease (CVD) regardless of the 
pathogenesis (e.g. cardioembolic, atherosclerotic, ischaemic, 
haemorrhagic, genetically-related CVD, and even potential 
interactions with Alzheimer’s Disease [AD] and other so-called 
neurodegenerative disorders). The VCI construct has also 
brought greater attention to to opportunities for prevention, 
early intervention, and the coexistence of AD pathology [5]. 
An overview of the neurobiological aspects of VCI that 
may be relevant to its management is beyond the scope of this 
paper, and in any case was recently thoroughly analysed in the 
consensus report by Bordet et al. [6].
Over the last decade, by recognising that only about half 
the population of patients with cerebrovascular pathology 
exhibit full blown dementia, the term VCI has become more 
appropriate to describe the whole spectrum of cognitive-be-
havioural deficits due to cerebrovascular pathology. Different 
approaches have been proposed for the classification of VCI, 
but no particular criteria set has gained universal acceptance. 
The five most common criteria sets are: the DSM-5 [7]; the 
International Classification of Diseases, 11th Ed (ICD 11) 
[8]; the State of California Alzheimer’s Disease Diagnostic 
and Treatment Centres (ADDTC) criteria [9]; the National 
Institute of Neurological Disorders and Stroke with the Asso-
ciation Internationale pour la Recherche et l’Enseignement en 
Neurosciences (NINDS-AIREN) criteria [10]; and VASCOG 
[11]. Although NINDS-AIREN and ADDTC are not funda-
mentally different, the latter do not include haemorrhagic and 
anoxic lesions. VASCOG criteria correspond to DSM-V [12].
Aim of the study
Understanding of the cognitive and behavioural aspects of 
VCI and their clinical assessment is still insufficient. 
This paper was aimed at reviewing published data on 
cognitive and behavioural disturbances through the whole 
spectrum of vascular cognitive impairment in order to propose 
a set of clinically accepted and valid testing procedures that 
could be used to identify patients with possible cognitive and/ 
/or behavioural disturbances in generic as well as in specialised 
neurological settings. 
By doing so, pertinent literature (excluding case studies) 
published in PubMed and MEDLINE (containing the search 
items “vascular dementia” OR “vascular cognitive impairment” 
AND “neuropsychology” OR “cognition” between 1990 and 
2020 was identified and reviewed by the workgroup. Our work-
group focused mainly on identifying diagnostic approaches 
applicable in different settings, as most other consortia or 
task-forces aim to improve the diagnosis and treatment of 
VCI [13] through standardising assessment and treatment 
approaches that seem to be based mainly on resources available 
from inpatient stroke units. 
As discussed above, the terminology related to VCI and 
VaD has changed over the years. According to O’Brien et 
al., vascular dementia itself has the following subtypes: mul-
ti-infarct dementia, small vessel dementia, strategic infarct 
dementia, hypoperfusion dementia, haemorrhagic dementia, 
hereditary vascular dementia and mixed dementia [1]. VaD 
may be also divided into subcortical (sVaD) and cortical 
(cVAD) [14]. Unfortunately, only in some of the studies has 
the clinical cohort been defined in line with this terminology. 
Also, we did not limit our search on VCI to dementia cohorts. 
Whenever available, when describing study results, we used 
more specific terms. 
Epidemiology of VCI
Vascular disease is a major cause of cognitive impairment 
and dementia, but is under-investigated and poorly character-
ised compared to Alzheimer’s Disease  (AD). Depending on the 
age cohorts under study, the prevalence estimates of VaD can 
vary substantially, generally showing an exponential increase 
in prevalence and incidence as age increases. These estimates 
seem to mirror the pattern of stroke, though dementia after 
stroke may be more frequent in the very elderly. Thus, while 
the World Federation of Neurology Dementia Research Group 
[15] has estimated VaD in developing countries to be in the 
range between 0.6% and 2.1%, a pooled analysis of European 
population-based studies reported VaD to be prevalent in 
1.6% of subjects over the age of 65, with substantial variation 
in 5-year age-specific prevalence rates. While some studies 
were able to show a higher incidence of VaD in men than in 
women [16], a pooled analysis of incidence studies found no 
sex differences [17]. Similarly to Western countries, AD is the 
leading cause of dementia in Asian populations. The preva-
lence of AD doubles every 4.3 years, whereas the prevalence 
of vascular dementia (VaD) doubles every 5.3 years. Recent 
reports from China have suggested that previous estimates of 
the dementia burden, based on smaller datasets, might have 
underestimated the burden of dementia in China to date [18]. 
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As indicated by a recent study in which dementia diagnosis 
was established on the basis of a cognitive screening (Montreal 
Cognitive Assessment, MoCA) three months after middle 
cerebral artery territory ischaemic stroke, dementia may be 
present in about 25% of cases [19]. Thus the frequency of VaD 
diagnosis could be be both underestimated and overestimated 
if patients with focal language and cognitive deficits are not 
neuropsychologically assessed. 
The heterogeneity of the VCI construct (principally the 
inclusion of the vascular variant of mild cognitive impairment, 
VaMCI) creates challenges for descriptive epidemiology, much 
of which still refers to VaD terminology. In the Canadian Study 
of Health and Aging, it was estimated that approximately 
5% of people over the age of 65 had VCI, with 2.4% having 
VaMCI, 0.9% having mixed dementia, and 1.5% having VaD 
[20]. Gorelick et al. [5] and Rincon and Wright [21] report the 
overall prevalence of VaD to be 5-10% in people older than 
65 years, and this increases rapidly thereafter,with a prevalence 
of as much as 50% of the population aged over 85. 
Is there a neuropsychological ‘fingerprint’ 
of VCI?
VCI has both cognitive and behavioural manifestations. 
VaMCI is characterised by executive dysfunction, slowed in-
formation processing, episodic memory deficits, with mood 
and personality disorders. Although there were significant 
differences in all cognitive domains between VCI without 
dementia and healthy controls, deficits in processing speed, 
working memory and visuospatial construction were more 
prevalent [22]. In contrast to VaMCI, non-vascular MCI had 
a greater relative deficit in episodic memory [22]. 
As mentioned above, VCI can present with a variety of 
neurocognitive symptoms which can be relatively mild or more 
severe. Although this view has been challenged [23], there are 
many studies indicating the preponderance of mental slowing 
in combination with executive dysfunction. The presence of 
memory impairment (of amnestic type) is highly suggestive of 
an AD profile, while executive impairment may appear both 
in non-vascular MCI and VaMCI. When analysing assessment 
results in a particular patient, the presence and significance of 
executive impairment based on quantitative scores has to be 
interpreted in the context of qualitative features and memory 
functioning [24]. Executive tests, being the most complex 
neuropsychological measures, are likely to be failed due to 
factors other than true executive impairments. 
The individual neuropsychological profile of VCI is highly 
dependent on the topography of the underlying vascular 
pathology, affecting either large or small vessels. If VCI is 
due to large vessel disease (LVD) and occurs post-stroke 
(sometimes referred to also as strategic infarct dementia), 
the neuropsychological profile is characterised mainly by 
focal deficits corresponding to the localisation of the stroke 
area (e.g. hemispatial neglect following an infarct in the right 
middle cerebral artery) (Tab. 1). In accordance with the overall 
clinical outcome, the severity of the neuropsychological seque-
lae differs according to different vascular incidents: worse for 
haemorrhagic than for ischaemic strokes, and less favourable 
for ruptures of arteriovenous malformations than for cerebral 
aneurysms [25].
Thalamic strokes are associated with the most heterogene-
ous clinical manifestations due to reciprocal connections with 
different cortical areas and several sources of vascular supply 
[26]. Similarly, strokes affecting the basal ganglia (termed silent 
lacunar infarcts) lead to various clinical manifestations, affect-
ing mainly language, memory and executive functions [27]. 
VCI, in the absence of stroke, is characterised by slowed 
information processing, impaired working memory and execu-
tive functions, episodic memory impairment, and visuospatial 
deficits. Thus, the neuropsychological pattern of VCI is not 
specific to the underlying vascular deficit, but rather reflects 
the disconnection of cortico-limbic loops that may be affect-
ed either due to vascular or to neurodegenerative pathology 
[27]. Information processing, working memory and executive 
function recruit complex brain networks and the severity of 
their impairment is significantly correlated to white matter 
pathology [28].
Update on neuroimaging correlates of VCI
Recent literature suggests that the presence of cognitive 
impairment post-stroke may be more closely related to struc-
tural global network competence than to traditional vascular 
burden scores that were popular in previous years [29]. Dete-
rioration in connectivity following vascular lesions seems to 
be the key to the development of cognitive impairment [30]. 
Also, novel MRI approaches show promise in differentiating 
between amnestic and non-amnestic VCI on the basis of 
single-shot T2-weighted fluid-attenuated inversion recovery 
(FLAIR) sequence [31]. As the severity of so-called frontal 
deficits is associated with a haemodynamic pattern indicative 
of cerebral hypoperfusion and enhanced vascular resistance on 
transcranial doppler (TCD) [32], the use of TCD may become 
more popular, especially in the follow-up of VCI patients, 
because its cost is lower than MRI. However, the sensitivities 
of the two methods to change need to be established.
Lesions along association white matter tracts mediating 
intrahemispheric long-range connectivity are related with 
psychomotor speed and constructional praxis. Non-amnestic 
deficits are associated with frontal white matter in particular 
[33]. Also, callosal fibres seem crucial in the pathophysiology 
of cognitive impairment in VCI [29]. Of note, there is an ongo-
ing study aimed at using a lesion-mapping approach that will 
hopefully elucidate the underlying basis of cognitive deficits 
in VCI [34] (Tab. 1). 
Cognitive assessment
The lack of specific cognitive tools that are sensitive enough 
to detect subtle deficits make the assessment of cognitive im-
pairment difficult. While much work has been done, e.g. in 
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AD [35], research into comparable protocols relating to VCI to 
detect subtle changes in cognitive performance is still scarce. 
Furthermore, culturally and linguistically relevant neuropsy-
chological tests are lacking in populations with a higher inci-
dence of stroke such as Asians, posing additional challenges 
to establish the prevalence of VCI in these populations. 
One of the attempts to standardise the neuropsychological 
protocol for VaMCI was the introduction of harmonisation 
standards published by the National Institute of Neurological 
Disorders and Stroke (NINDS) and the Canadian Stroke Net-
work (CSN). The authors proposed three neuropsychological 
test protocols of different lengths (60, 30, and 5 minute pro-
tocols) to be used in different settings which could evaluate 
the following cognitive domains: executive functions (using 
categorical and letter fluency and Digit Symbol-Coding sub-
test from Wechsler Adult Intelligence Scale-III (WAIS-III), 
visuospatial functions (Rey-Osterrieth Complex Figure), lan-
guage (Boston Naming Test), memory (Hopkins Verbal Lear-
ning Test-Revised or California Verbal Learning Test-2) and 
neuropsychiatric and depressive symptoms (Neuropsychiatric 
Inventory, NPI) [36]. However, a VCI-subgroup-specific vali-
dation of those tests still remains to be carried out.
Following VASCOG criteria [11], there have been efforts 
to create summary scores that would enable the detection of 
cognitive impairment post stroke [37]. The drawback of the 
the proposed battery is the issue that selective but clinically 
important deficits (e.g. apraxia) might be missed by such 
summary scores. 
Multilevel assessment of cognitive impairment 
in VCI 
Since focal cognitive deficits, as well as overall cognitive 
decline, may be present in VCI, neuropsychological testing 
should consider both domain-specific neuropsychological 
disturbances (e.g. neglect) as well as global deterioration 
(e.g. dementia). As most patients with suspected VCI are of 
advanced age and suffer from fatigue, reduced attention ca-
pacity, behavioural alterations and other comorbid conditions, 
the testing needs to be relatively short or divided into two or 
more sessions. Moreover, significant sensory problems may 
exist, precluding the use of some cognitive tests with a special 
emphasis on these sensory abilities. In general, qualitative 
descriptions of cognitive symptoms are less favourable com-
pared to operational definitions of cognitive impairment (e.g. 
performance 1 or 1.5 standard deviations below that of an 
appropriate comparison group) [5].
Hence, we suggest a 2-level assessment procedure, con-
sisting of a primary screening (level A) which, at least in part, 
should also offer the possibility to be used at the bedside, plus 
a thorough evaluation (level B). This approach also takes into 
account the setting in which the neuropsychological assess-
ment takes place (Tab. 2). Thus, while in the primary care 
setting (family physician or allied health professional) there is 
a need for time-efficient, global and sensitive cognitive mea-
sures, specific settings have different requirements: intensive 
care units (stroke units) follow a more tailored approach using 
measures that are able to identify specific deficits or core-syn-
dromes (e.g. aphasia, apraxia), while memory clinic services 
are generally located more downstream in the diagnostic 
algorithm, thus allowing more in-depth protocols in order 
to postacutely describe the cognitive and behavioural profile 
for prognostic and rehabilitative purposes. When there are 
abnormal results in level A, patients should be referred to level 
B facilities, in order to i) submit them to a more specialised 
diagnostic setup once vascular pathology is suspected on the 
basis of level A findings, or ii) to optimise therapeutic efforts on 
the basis of an extended cognitive and behavioural assessment.
Neuropsychological tools should also offer the possibility 
of documenting changes over time in clinical status. As atten-
tion and executive deficits are regarded as core symptoms of 
VCI, particular measures should be used that are supposed to 
identify these deficits. However, since time-consuming and 
multiple-domain-involving tasks may obscure the under-
lying core deficit, neuropsychological testing should include 
straightforward as well as complex procedures. Moreover, in 
order to avoid ceiling, floor and practice effects, simple and 
short tasks with validated parallel versions, if available, should 
be administered. 
Importantly, it must be considered that different tests have 
different sensitivities in different stages of a cognitive trajec-
tory. Thus, while some tests (e.g. working memory-related 
tasks) may be useful in documenting incipient decline, they 
Table 1. Pattern of most common focal neuropsychological deficits related to localization of infarcts
Localisation of infarct Most common possible neuropsychological consequences
Left anterior cerebral artery Executive dysfunction, aphasia
Right anterior cerebral artery Executive dysfunction
Anterior communicating artery Executive dysfunction; amnesia, aphasia
Left middle cerebral artery Aphasia, apraxia, acalculia, verbal memory impairment
Right middle cerebral artery Unilateral neglect, aprosody, spatial memory impairment
Posterior communicating artery Memory impairment
Left posterior cerebral artery Alexia, verbal memory impairment
Right posterior cerebral artery Unilateral neglect, spatial memory impairment
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Table 2. Extended neuropsychological assessment 
Stroke clinic Memory clinic
Battery approach Birmingham Cognitive Screen (BCoS); if no deficits evidenced – more 
extended memory and executive testing (see below)
Repeatable Battery for Assessment of Neuropsy-
chological Status (RBANS); if no deficits evidenced 
– more extended executive testing (see below)
Tailored testing Aimed at capturing focal syndromes as well as overall cognitive effi-
ciency, so as to diagnose VCI or VaD
Aimed at specifying pattern of deficits to help 
with differential diagnosis
Language Minimal assessment: naming, repetition, comprehension Naming (e.g. BNT, SydBAT) comprehension  
(e.g. commands from BDAE)
Visuospatial functions VOSP, line bisection, cancellation tasks VOSP (Incomplete letters, Cube analysis)
Praxis Praxis tasks with one hand (without motor impairment) Interlocking fingers test
Episodic memory If no aphasia and/or hearing impairment: CVLT/RAVLT/other verbal learning task
For individuals with particularly slowed information processing and/or impaired hearing: verbal learning lists presented 
visually (rate of presentation is adjusted to patient’s slowing) 
If visuospatial functions are mostly preserved:  
Location Learning Test 
BVMT-R
Working memory Months backwards; serial sevens, Digit Span, Spatial Span, TMT
Executive functions If confrontation naming is preserved: phonemic fluency tasks 
if visuospatial function is relatively preserved: Weigl block sorting task, picture sequencing task, Tower tests, Brixton Spatial 
Anticipation Test
BDAE — Boston Diagnostic Aphasia Examination; BNT — Boston Naming Test; BVMT-R — Brief Visuospatial Memory Test-Revised; CVLT — California Verbal Learning Test; RAVLT — Rey Auditory Verbal Learning 
Task; SYDBAT — Sydney Language Battery; TMT — Trail Making Test; VCI — Vascular Cognitive Impairment; VaD — Vascular Dementia; VOSP — Visual Object and Space Perception Test
show a plateau (the floor effect) in more advanced stages and 
do not offer any specific diagnostic information. Hence for 
monitoring purposes it is mandatory to use tests which have 
more linear decelerating properties (e.g. semantic fluency and 
flexibility-related tasks). As information processing speed is 
usually compromised in VCI, in tasks assessing other aspects of 
cognition, the scoring should not be entirely time-dependent. 
Finally, a neuropsychological diagnosis should consider 
both quantitative and qualitative data and take into account the 
apparent validity of the cognitive measures used. In some cases, 
one prominent deficit (e.g. executive deficit) may lead to low 
scores in almost all tasks. Conversely, some singular tests may 
require a set of different abilities and functions, thus qualifying 
them as global screening procedures and economising time 
for administration. Consequently, neuropsychological test 
results need to be interpreted in the context of behavioural 
observations, as a purely quantitative approach can lead to 
false conclusions. 
Brief cognitive screening tests
The most commonly used instrument, MMSE, has only 
a low sensitivity in detecting MCI [38]. Using MMSE, only 
one study has provided information about conversion from 
MCI to VaD, presenting a sensitivity of 36%, and a specific-
ity of 80% with incidence of VaD of 6.2% [39]. Despite the 
greater than MMSE sensitivity of MoCA to the milder forms 
of cognitive impairment with cerebrovascular disease [40], 
further longitudinal research is needed to verify its validity 
in detecting the progression of VCI [41]. A cut-off of 24/25 is 
suggested to detect post-stroke cognitive impairment [42]. 
However, MoCA is not sensitive enough to information 
processing deficits and visual memory impairment that are 
common in stroke survivors [43]. Also, it is much less sen-
sitive to cognitive impairment following right-hemisphere 
strokes [44].
The short NINDS-CNS is a 5-minute protocol that can be 
used to identify high-risk groups for post-stroke dementia after 
acute ichaemic stroke. However, this test has been employed 
only in Korea [45] and China [46]. 
The cognitive screening instrument DemTect [47] is a short-
screening test that has been extensively validated in different 
settings and languages. It was first published in 2000 in a Ger-
man version, then in 2002 in a French, in 2004 in an English 
[48], and in 2016 in a Polish version [49]. In 2010, a parallel 
test, the DemTect B, was published [50] and in 2013, norms for 
people below 40 years and over 80 years were added [51]. In 
2010, a modification of DemTect was developed by a Canadian 
workgroup to identify at-risk drivers [52]. DemTect consists of 
five subtests measuring short and long-term verbal memory, 
working memory, executive function, and number processing. 
The administration time is 8–10 minutes. Sensitivity and speci-
ficity of DemTect in studies with patients with dementia or MCI 
and healthy controls has been summarised in Kalbe et al. [53]. 
A condensed version which is suited for primary care settings 
is also available (RDST, rapid dementia screening test) [54].
Another screening instrument has recently been developed 
specifically for vascular MCI: the Brief Memory and Execu-
tive Test (BMET) covering executive functioning, processing 
speed, orientation, and memory [55]. MoCA and BMET are 
more sensitive in the detection of VCI than MMSE [56]. 
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Cognitive dysfunction (evidenced by clinical 
history or reported by proxy) 
COGNITIVE ASSESSMENT
Level A Level B 
Primary care setting Specialised setting
Brief screenings 
(DemTect, MoCA, 
BMET, OCS, Clock Drawing, 






memory, visuospatial, praxis, 
calculation, executive) 
Neurology / Stroke Units 
BCoS or tailored testing 
(e.g. aphasia screening, 
line bisection, etc.) 
Refer to a Memory Clinic 3 months 
after stroke if daily function 
is affected OR cognitive impairment 
was found in the acute phase
Refer to a  specialised 
setting if positive
Figure 1. Cognitive assessment if vascular cognitive impairment is suspected.
BCoS — Birmingham Cognitive Screen; BMET — Brief Memory and Executive Test; CERAD+ — Consortium to Establish a Registry for 
Alzheimer’s Disease; DemTect — Demenz Detection; MoCA — Montreal Cognitive Assessment; OCS — Oxford Cognitive Screen
The Oxford Cognitive Screen (OCS) incorporates tests 
for five cognitive domains: executive function, language, 
memory, number processing, and praxis [57], while the 
Cognitive Assessment for Stroke Patients (CASP) address-
es language, visuospatial function, memory, praxis, and 
executive function [58]. CASP, unlike MMSE and MoCA, 
is applicable also in aphasic patients [59]. Both OCS and 
CASP address hemispatial neglect and apraxia. These are 
far more important in VaD than in neurodegenerative de-
mentias. Although the diagnostic value of the Clock Draw-
ing Test (CDT) depends on the scoring method, including 
quantitative and qualitative aspects [60], it is also regarded 
as a useful screening tool. Therefore it is recommended in 
a primary care setting since it probes executive as well as 
spatial functions. CDT together with a word learning trial, 
a letter fluency procedure and a naming task, is regarded as 
suited to a primary care setting to identify global cognitive 
deficits (Figure 1). Depending on the available assessment 
time and the patient’s condition, these tasks can be either 
administered as single tasks or combined in a compre-
hensive short screening (e.g. MoCA, DemTect). Also, the 
Trail Making Test is sometimes recommended in the short 
screening context [61]. VASCOG experts suggest also other 
test combinations for shorter and longer screening, with 
semantic fluency - animal naming being the most commonly 
recommended measure [62].
Overall, cognitive screening tests, originally developed to 
screen for cognitive deficits in memory clinics, are not optimal 
measures to screen for cognitive impairment during the first 
month post stroke [63]. 
An alternative method for cognitive screening is the 
NeuroPsychological Examination (NPE). NPE is based on 
observation of the patient’s behaviour during an examina-
tion. This semi-structured interview gives an opportunity to 
examine patients and acquire information about their daily 
functioning. However, its validity is strongly dependent on 
the clinician’s experience [64] (Fig. 1).
Assessment of VCI at a stroke unit
Specialised units (e.g. stroke units/memory clinics) gen-
erally offer a far more sophisticated approach due to their ex-
tended resources in terms of time and personnel. Nonetheless, 
considering the patient’s overall status when referred to these 
units, the examination procedure is presumed to be short and 
adaptable. As aphasia and unilateral neglect are quite common 
in stroke survivors, and most traditional neuropsychological 
assessments are not designed for people with language and/ 
/or hemispatial deficits, cognitive assessment at stroke units 
is particularly challenging e.g. when disentangling executive 
or memory deficits that might exist secondary to language or 
perceptual problems. Hence, some of the above-mentioned 
tests can be used or, alternatively, some intermediate batteries 
may turn out to be useful. As an example, the Birmingham 
Cognitive Screen (BCoS) offers the possibility to test cognition 
with minimal involvement of speech (e.g. orientation in time 
is tested in a multiple choice format). There is only a basic 
requirement of spatial attention (e.g. vertical alignment of 
stimuli), also probing for important cognitive aspects that are 
not included in most neuropsychological test batteries (praxis, cal-
culation, spatial attention) [65]. Since this approach may contain 
339www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Pasquale Calabrese et al., Assessment of VCI
areas that could not adequately be assessed in some cases, a flexible 
battery of neuropsychological tests may be adopted. 
Such a flexible battery involves the selection and admi-
nistration of an array of tests that are based on the neuro-
psychologist’s perception of the kind of brain damage that 
is allegedly present. Regarding the symptom variability, tests 
should probe the information processing speed, semantic and 
phonemic fluency, set-shifting, verbal learning (including free 
and cued short- and long-term recall), visuospatial functions 
and language abilities, as well as praxis and calculation. 
Assessment of VCI at a memory clinic
Patients with suspected VCI are referred for neuropsycho-
logical assessment at a memory clinic usually in the context 
of a differential diagnosis with a primary neurodegenerative 
disease such as AD, dementia with Lewy bodies (DLB), or 
frontotemporal-dementia (FTD). Most memory clinics use 
a comprehensive and fixed battery of tests, all of which were 
standardised on the same group of people. This approach is 
called a fixed comprehensive standardised test battery. 
The most commonly used test following this approach 
is the CERAD-NAB (Consortium to Establish a Registry for 
Alzheimer‘s Disease – Neuropsychological Assessment Bat-
tery). Though this battery was constructed to assess cognitive 
disturbances in suspected AD, and hence focuses primarily on 
cortical functions, a more recent extension of this battery was 
validated [66] by adding measures of speed and flexibility in 
order to improve diagnostic acuracy in VaD. 
In case of a flexible approach, the cognitive assessment 
protocol should comprise at least one memory task with 
spontaneous delayed recall followed by either cued delayed 
recall or recognition to discriminate between storage (typical 
for AD and other pathologies involving the hippocampus) and 
retrieval deficit (typical for subcortical dementias). However, 
as neuropsychological profiles of VCI and DLB may overlap, 
neuropsychological assessment seems more promising in dif-
ferentiating between VCI and AD than between VCI and DLB. 
Mixed dementia (MD), i.e. the coexistence of Alzheimer‘s 
Disease (AD) and cerebrovascular disease (CVD), is a com-
mon dementia subtype [67]. It is increasingly recognised that 
patients with dementia and probable AD dementia commonly 
have mixed pathologies contributing to cognitive impairment. 
A study by Lei et al. [68] of 653 autopsied cases from two 
ongoing longitudinal cohort studies of individuals who were 
cognitively healthy at baseline (mean age = 79.1 years) analy-
sing cognitive and neuropathological features, showed patients 
with AD pathology alone doubled the odds of developing 
dementia, and patients displaying mixed pathologies such 
as AD with macroinfarcts and/or Lewy body (LB) pathology 
markedly increased the odds, suggesting that AD pathology as 
well as vascular pathology are both associated with cognitive 
impairment. 
Several studies have reported macroscopic and micro-
scopic infarcts as well as amyloid angiopathy to be associated 
with a decline in perceptual speed and episodic memory loss 
[69]. In light of the striking overlap between AD and VaD 
contributing to cognitive impairment, it is difficult to establish 
a profile specific to degenerative or to vascular pathology. One 
of the few comparative studies, performed by Dong et al. [70], 
found the neuropsychological profile of patients with MD of 
mild-moderate severity to be characterised by a poorer global 
cognitive performance, as well as attention and visuocons-
truction, than those with AD of mild-moderate severity. The 
TRACE–VCI study aimed to define the phenotype of VCI 
in a memory clinic setting by comparing different forms of 
vascular brain damage such as white matter hyperintensities, 
lacunar and non-lacunar infarcts and microbleed. However, 
the cognitive profiles of these vascular brain injuries were 
not signicantly different regardless of co-occurring AD [71]. 
Taken together, the neuropsychological differentiation 
between AD and MD still remains a diagnostic challenge. More 
comparative studies adopting comprehensive neuropsycholo-
gical test batteries are needed to establish the cognitive profiles 
of mild-moderate MD, and compare it to the profiles of AD. 
A more focused approach may also benefit from qualitative 
data on memory profile. Considering the performance pattern 
in verbal learning tasks, patients with AD profile reveal marked 
recency effect and less prominent primacy effect, while in MCI 
related to white matter hyperintensities either the opposite 
pattern or low serial position effects may be observed [72].  
Behavioural and psychological symptoms  
in VCI/VaD
Behavioural and psychological symptoms of dementia 
(BPSD) affect almost all people at some point during the 
progression of VCI/VaD. In community-based studies, the 
prevalence of BPS ranges from 60% to 93% [73], whereas 
in memory units it is higher, ranging from 85% to 100% 
[74–76]. Besides the type of population (clinical, community 
or nursing-home settings), the definition of VCI/VaD and the 
instruments used to study the symptoms, differences in the 
prevalence and patterns of BPS between various studies may 
be due to other, often unconsidered, factors such as gender, 
age, education, use of medication and VCI/VaD severity. 
In fact, except for depression, anxiety and euphoria, the 
frequency and diversity of BPS increases with the severity of 
cognitive impairment, leading to agitation, hallucinations, 
irritability, and disinhibition [75, 77]. There is still contro-
versy regarding differences in BPS in different patient groups. 
While some authors have proposed that overall frequency and 
severity of BPS are higher in patients with VaD than in those 
with AD [77], some other groups have reported no significant 
difference [73, 74, 76, 78]. 
Although the literature dealing with BPSD in VCI/VaD 
is modest, some of these symptoms have been included in 
the criteria proposed for a diagnosis of VaD. The Hachinski 
Ischaemic Scale, a tool thought to be helpful in the differentia-
tion of AD (cut-off score ≤ 4) from VaD (score ≥ 7), gives one 
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point for each of the following features: relative preservation 
of personality, depression and emotional incontinence [79]. 
Similarly, the NINDS-AIREN criteria include personality and 
mood changes, abulia, depression and emotional incontinence 
in the clinical features consistent with the diagnosis of probable 
VaD [10]. Most studies that have relied on VaD terminology 
have shown apathy to be the most common symptom (23–94%; 
[75]), followed by depression (21–85%; [73]), irritability 
(18–78%; [75, 76]), sleep disturbances (4–78%; [76, 78]) and 
agitation (21–77%; [75, 78]). Euphoria was the least common 
symptom (1.6–25%; [76]). A median number of three symp-
toms per patient has usually been reported [80]. 
When comparing VaD to AD, the most consistent findings 
are higher prevalence of delusions, aberrant motor behaviours 
[73, 74, 78], and hallucinations [74, 75] in AD. Other BPS 
such as agitation, anxiety, sleep disturbances and changes in 
appetite have been reported as being more common in AD in 
some studies, and in VaD in others [74, 76–78]. Compared 
to patients with DLB, patients with VaD had a lower score 
in hallucinations, agitation, irritability, anxiety and aberrant 
motor behaviours [74]. In contrast to FTD, disinhibition, 
aberrant motor behaviour and changes in appetite were less 
frequent in VaD [75]. 
These inconsistent results may be due to the fact that VCI/VaD 
is a heterogeneous entity with multiple causes (large vessel 
disease, small vessel disease, haemorrhagic stroke, strategi-
cally located lesions) being characterised by various clinical 
presentations. There appear to be differences in the individual 
BPS symptoms between sVaD and cVaD. Patients with sVaD 
had a higher severity of apathy [14, 80], aberrant motor be-
haviour and hallucinations [80] than patients with cVaD. In 
VaD, agitation and sleep disturbances are more common than 
in AD patients, and depression and aberrant motor behavi-
ours appear more commonly in VaD than in mixed AD/VaD 
patients [81]. In contrast, symptoms of agitation [77, 80], 
sleep disturbances [77], and euphoria [80] were more severe 
in cVaD compared to sVaD. 
In the most recent study, euphoria, apathy, irritability 
and agitation were more common in cVaD than in AD, while 
apathy and irritability were more frequent in sVaD than in AD. 
Psychotic symptoms and aberrant motor behaviour were more 
common in AD. A higher risk of euphoria, apathy, irritability 
and sleep disturbance was found in cVaD than in AD, and more 
apathy and irritability in sVaD than in AD. In contrast, AD 
subjects had a higher risk of delusions and hallucinations than 
patients with cVaD, as well as more aberrant motor behaviour 
than both cVaD and sVaD [82].
Recently there has been a tendency to conceptualise BPSD 
into “clusters” of symptoms that appear together: a) “affective” 
(including depression, anxiety); b) “apathy” (apathy, reduced 
appetite); c) “hyperactivity” (agitation, euphoria, irritability, 
disinhibition); and d) “psychosis” (hallucinations, delusions, 
abnormal motor behaviour (AMB) and sleep disturbances) 
[83]. Others have described three clusters: a) “mood” (anxiety, 
apathy, dysphoria); b) “psychosis” (irritability, delusions, 
hallucinations, agitation); and c) “frontal” (euphoria and 
disinhibition) in VaD [84].  
Finally, it has been debated whether some BPSD in VaD 
are clinically distinct from those in other types of dementias. 
For example, compared to depression in AD, psychomotor 
symptoms such as loss of energy, and vegetative symptoms 
such as weight loss and loss of appetite, have been reported 
to be more prevalent in depression co-occurring within VaD 
[85]. One of the scales most commonly used to assess BPSD 
symptoms is the Neuropsychiatric Inventory (NPI), covering 
12 areas of BPSD [86]. In addition, there are also available 
scales focused on the assessment of specific BPSD. Commonly 
used screening tests for depression in patients with suspected 
VCI include the Geriatric Depression Scale, the nine-item 
Patient Health Questionnaire, the Beck Depression Inventory, 
and the Centre for Epidemiologic Studies Depression Scale 
[87–89]. The Stroke Aphasic Depression Questionnaire or 
the Depression Intensity Scale Circles can be used to identify 
mood disturbance in VCI patients with aphasia [90, 91]. The 
Hamilton Depression Rating Scale and Hospital Anxiety and 
Depression Scale [HADS] are anxiety- and depression-specific 
case-finding instruments validated for use in stroke research 
[87, 92]. Also apathy can be identified by informant-rated 
specific scales such as the Apathy Evaluation Scale [93]. Of 
note, the presence of baseline VCI is predictive of apathy but 
not depression at 12-month follow-up [94]. 
The BPSD are associated with shorter life expectancy, 
excess disability, impaired quality of life for subjects and 
carers, high levels of caregiver distress, early institutionali-
sation, and increased direct cost of care. However, BPSD can 
be treated efficiently to improve the situation when correctly 
diagnosed [95].
The Neuropsychiatric Inventory Caregiver Distress Scale 
(NPI-D) is an instrument that provides a quantitative measure 
of the distress experienced by caregivers in relation to the 
individual symptom domains assessed by the NPI [96]. The 
Zarit Burden Interview (ZBI) is another validated and com-
prehensive instrument measuring caregiver burden [97]. Since 
the interview is a statement which the caregiver is asked to 
endorse, it is less appropriate to evaluate the burden associated 
with individual BPSD.
Prognosis and long-term management
Applying DSM–V criteria for major neurocognitive dis-
orders (NCD) helps with defining a psychometric threshold 
for transition from MCI and small vessel disease (SVD) to 
major NCD. A longitudinal observation of 138 patients found 
that one–third of the multi–domain MCI patients with SVD 
progressed to major NCD after two years [98]. Interestingly, 
post-stroke cognitive impairment (PSCI) may be more closely 
related to the overall integrity of brain tissue that the volume 
of the new ischaemic lesion, as proved in a study in which 20% 
of patients developed PSCI during a 2-year observation [99]. 
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Post-stroke VCI, unlike MCI in the context of neurodegen-
erative diseases (e.g. AD or Parkinson’s Disease), or VCI with 
small vessel disease (VCI/SVD), may be quite stable for a cou-
ple of years and may thus hinder long-term prognosis about 
the conversion from VCI (at the mild cognitive impairment 
stage) to overt VaD. In VCI due to SVD, the conversion of VCI 
to VaD is usually heralded by the emergence of parkinsonian 
features. Thus, in a case of SVD or genetically caused vascu-
lar pathologies that are known to have a progressive course 
(e.g. cerebral autosomal dominant/recessive arteriopathy 
with subcortical infarcts and leukoencephalopathy — CA-
DASIL / CARASIL, and mitochondrial encephalomyopathy 
lactic acidosis with stroke-like episodes — MELAS), regular 
neuropsychological follow-ups may be required to track the 
disease progression and formulate the recommendations for 
the patient and his/her family. 
Such recommendations should include the preparations 
of powers of attorney for property and personal care, and the 
patient’s ability to manage medication, which is particularly 
important in individuals with co-morbid insulin-dependent 
diabetes. Similarly, the impact of VCI on driving capacity 
needs to be considered. 
Summary
Vascular cognitive impairment is an umbrella term com-
prising different forms and stages of cognitive decline, ranging 
from mild impairment to overt dementia. It is characterised 
most commonly by progressive accumulation of microvascular, 
or subcortical strokes, which results in progressive neurological 
dysfunction and cognitive as well as behavioural disturbances. 
Dementia due to vascular damage is widely considered to 
be the second most common cause of dementia after AD. The 
diagnosis of vascular dementia is based on the presence of cer-
ebrovascular disease of different origins, the identification of 
cognitive dysfunction, and a likely causal relationship between 
the two. Thus, once other causes of cognitive impairment have 
been excluded, the diagnosis can be established, if cognitive, 
as well as behavioural and motor symptoms characteristic of 
vascular origin and evidence of stroke or white matter lesions 
on neuroimaging arise. Given the various pathologies leading 
to VCI, it is no surprise that clinical symptoms can vary sub-
stantially in individual patients. Nonetheless, some cognitive 
features, executive dysfunctions, together with a reduced pro-
cessing speed and failures of episodic memory are common, 
and make neuropsychological assessment mandatory. 
Given that patients with vascular deficits can appear in 
different clinical settings, we suggest a two-level assessment 
procedure consisting of a primary short screening (level A) 
and an in-depth evaluation (level B). This proposal is in agree-
ment with a recent UK consensus on VCI which advocates 
the same approach, stating that a single mandated outcome 
assessment would not be suitable for a complex construct 
such as VCI [100].
Behavioural disturbances are also common in VCI and 
may even dominate the clinical picture at some stages, leading 
to a significant caregiver burden. Compared to AD, there is still 
a great need for prospective, cross-sectional and longitudinal 
studies on BPS in VCI. Although there are no consensus crite-
ria about the methodology for screening and investigating BPS 
in VCI, it is strongly recommended to use standardised pro-
tocols to assess BPSD (NPI) as well as caregiver burden (ZBI). 
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